INTRODUCTION
============

Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is an approved medical reperfusion treatment in acute ischemic stroke patients \[[@r1]\]. Recent studies revealed that a substantial fraction of patients cannot virtually recover but experienced early worsening following IVT, which were termed as early neurological deterioration (END) \[[@r2]\]. In fact, END may be accountable for living in dependence and even death, which were not surprisingly found in about half of the stroke survivors, despite IVT \[[@r3], [@r4]\]. Besides, older age, hyperglycemia, stroke severity, infarct volume, and vascular occlusion have been reported to be associated with a potentially increased risk of poor functional outcome after IVT \[[@r3], [@r5]\]. However, clinical outcomes are not easily foreseen at the initiation of the therapy as most of the current clinical-radiological risk factors are non-specifc (e.g., advanced age, stroke severity, symptomatic intracerebral hemorrhage, etc.). Therefore, it is essential to detect a potentially useful biomarker, which is involved in the underlying pathophysiological pathway and confers significant predictive value regarding therapy outcomes after IVT.

Subclinical thyroid dysfunction is a common endocrine condition among general population, including a prevalence reaching up to 15% for subclinical hypothyroidism (SHypo), and 12% for subclinical hyperthyroidism (SHyper) \[[@r6]--[@r9]\]. The cardio-cerebral vascular system is one of the major targets of thyroid hormones \[[@r6], [@r10], [@r11]\]. SHypo has been displayed to propagate vascular risk factors, such as hyperlipidemia \[[@r12]\], metabolic syndrome \[[@r13]\] and vascular stiffness \[[@r14]\]. SHyper has been proved to promote vascular damage by numerous ways, including facilitating hypertension, maintaining hypercoagulable state and causing endothelial dysfunction \[[@r15], [@r16]\]. Intriguingly, researchers found that ischemic stroke patients with SHypo or SHyper exhibited totally opposite outcomes \[[@r17], [@r18]\]. SHypo has been reported to be associated with favorable prognosis, while SHyper is related to poor outcomes.

IVT for acute ischemic stroke is often associated with hemorrhagic complications, such as symptomatic or asymptomatic intracerebral hemorrhage, mucosa bleedings and ecchymosis \[[@r19]\]. Thyroid diseases associated with thrombolysis are extremely rare. However, cases of thyroid hemorrhage have been reported \[[@r20], [@r21]\]. Besides, rt-PA can liberate bradykinin, causing vasodilation and capillary leakage in thyroid \[[@r22]\]. Recently, a case of transient thyroid edema has been confirmed following intravenous thrombolysis for acute ischemic stroke \[[@r23]\]. Thus, we hypothesized that IVT treatment may change the roles of thyroid function in predicting the clinical outcomes of ischemic stroke patients. Several cross-sectional studies have validated the predictive effects of thyroid function on prognosis in ischemic stroke patients \[[@r17], [@r18], [@r24]\], while there are yet no data on the prognostic value of subclinical thyroid dysfunction patterns in ischemic stroke patients treated with IVT. Herein, we aimed performed this prospective cohort to identify whether a potential prognostic value was existed in thyroid function in relation to short- and long-term outcomes of IVT patients and whether different dysfunction patterns would possess distinct prognostic values.

RESULTS
=======

Finally, 563 ischemic stroke patients (mean age, 67.0 ± 11.8 years; 58.4% male) with thrombolytic therapy were recruited. Flow chart of patient inclusion was present in [Figure 1](#f1){ref-type="fig"}. The baseline characteristics between patients included and patients excluded were shown in [Table 1](#t1){ref-type="table"}.

![**Flow chart of patient inclusion.**](aging-11-102215-g001){#f1}

###### Baseline characteristics of the included and excluded patients.

  -------------------------- -------------------------------- --------------------------------- ---------
  **Variable**               **Study population (n = 563)**   **Excluded subjects (n = 140)**   ***P***
  Age, year                  67.0 ± 11.8                      68.2 ± 10.2                       0.270
  Male,%                     329 (58.4)                       92 (65.7)                         0.124
  Hypertension,%             390 (69.3)                       105 (75.0)                        0.184
  Diabetes mellitus,%        151 (26.8)                       38 (27.1)                         0.939
  Hyperlipidemia,%           72 (12.8)                        19 (13.5)                         0.507
  Coronary heart disease,%   99 (17.6)                        28 (19.9)                         0.536
  Smoking,%                  207 (37.0)                       59 (42.1)                         0.265
  -------------------------- -------------------------------- --------------------------------- ---------

After admission, SHypo, SHyper and euthyroidism were found in 96 (17.1%), 56 (9.9%) and 411 (73.0%) patients, respectively. END was observed in 83 (14.7%) patients. Of the 563 patients, 50.8% developed poor outcome, and 9.4% died at 3 months. Compared with euthyroidism, patients with SHypo had a higher prevalence of diabetes and coronary heart disease, higher triglyceride levels, but a lower baseline NIHSS score. Furthermore, hypertension, END, poor outcome and mortality at 3 months were more common in patients with SHyper compared with patients with euthyroidism ([Table 2](#t2){ref-type="table"}).

###### Baseline characteristics of the study population stratified by the status of subclinical thyroid function.

  ----------------------------------- ---------------------------------- --------------------------- ------------- -------------------------- -------------
  **Variable**                        **Euthyroidism group (n = 411)**   **SHyper group (n = 56)**   ***P*^\*^**   **SHypo group (n = 96)**   ***P*^\#^**
  **Demographics data**                                                                                                                       
   Age, year                          67.3 ± 11.7                        65.1 ± 11.2                 0.207         66.8 ± 12.9                0.691
   Male, %                            247 (60.1)                         33 (58.9)                   0.867         49 (51.0)                  0.105
  **Vascular risk factors, %**                                                                                                                
   Hypertension                       283 (68.9)                         48 (85.7)                   0.009         59 (61.5)                  0.164
   Diabetes mellitus                  105 (25.5)                         12 (21.4)                   0.505         34 (35.4)                  0.049
   Hyperlipidemia                     50 (12.2)                          5 (9.1)                     0.477         17 (17.7)                  0.155
   Coronary heart disease             67 (16.3)                          8 (14.5)                    0.739         24 (25.0)                  0.046
   Atrial fibrillation                115 (28.0)                         20 (35.7)                   0.231         26 (27.1)                  0.860
   Smoking                            157 (39.0)                         19 (36.5)                   0.806         31 (32.3)                  0.273
  **Clinical data**                                                                                                                           
   Previous antiplatelet, %           85 (20.7)                          13 (24.5)                   0.524         17 (17.7)                  0.506
   Previous statin, %                 34 (8.3)                           7 (12.5)                    0.294         10 (10.4)                  0.502
   Systolic blood pressure, mmHg      136.8 ± 20.9                       137.5 ± 24.8                0.760         136.2 ± 21.3               0.892
   Diastolic blood pressure, mmHg     88.1 ± 14.8                        85.4 ± 14.5                 0.217         86.2 ± 12.8                0.252
   Body mass index, kg/m^2^           24.1 ± 3.2                         24.5 ± 3.8                  0.366         24.4 ± 3.2                 0.451
   Onset to blood drawing time, h     11.0 (6.0, 17.0)                   11.0 (6.0, 16.0)            0.592         10.0 (6.0, 15.0)           0.277
   Baseline NIHSS, score              8.0 (4.0, 13.0)                    11.0 (4.0, 19.0)            0.076         5.0 (3.0, 11.0)            0.010
   Onset to treatment time, minutes   144.8 ± 61.4                       148.7 ± 69.0                0.657         142.6 ± 65.0               0.767
  **Imaging data**                                                                                                                            
   ASPECTS at admission               9.0 (9.0, 10.0)                    9.0 (9.0, 10.0)             0.616         9.0 (9.0, 10.0)            0.793
   ASPECTS at 24 h                    8.0 (6.0, 9.0)                     7.0 (5.0, 9.0)              0.061         8.0 (6.0, 9.0)             0.384
   Vascular occlusion, %^†^           178 (46.6)                         30 (56.6)                   0.183         47 (51.1)                  0.465
   sICH, %                            22 (5.4)                           6 (10.7)                    0.113         2 (2.1)                    0.174
  **Lesion location, %**                                                                             0.467                                    0.815
   Frontal lobe                       98 (23.8)                          19 (33.9)                                 19 (19.8)                  
   Parietal lobe                      40 (9.7)                           4 (7.1)                                   7 (7.3)                    
   Basal ganglia                      118 (28.7)                         16 (28.6)                                 31 (32.3)                  
   Posterior fossa                    76 (18.5)                          10 (17.9)                                 19 (19.8)                  
   Other                              79 (19.2)                          7 (12.5)                                  20 (20.8)                  
  **Stroke subtype, %**                                                                              0.116                                    0.364
   Large artery atherosclerosis       161 (39.2)                         29 (51.8)                                 41 (42.7)                  
   Cardioembolism                     107 (26.0)                         14 (25.0)                                 20 (20.8)                  
   Small vessel occlusion             88 (21.4)                          11 (19.6)                                 26 (27.1)                  
   Others                             55 (13.4)                          2 (3.6)                                   9 (9.4)                    
  **Clinical outcomes, %**                                                                                                                    
   Early neurological deterioration   56 (13.6)                          19 (33.9)                   0.001         8 (8.3)                    0.160
   Unfavorable outcome at 3 months    205 (49.9)                         40 (71.4)                   0.003         41 (42.7)                  0.206
   Mortality at 3 months              33 (8.0)                           16 (28.6)                   0.001         4 (4.2)                    0.190
  **Thyroid function tests**                                                                                                                  
   TSH, mIU/L                         1.3 (0.9, 1.7)                     0.3 (0.2, 0.4)              0.001         3.4 (2.8, 4.1)             0.001
   Free T3, pmol/L                    4.8 ± 0.9                          4.9 ± 0.9                   0.603         4.8 ± 0.9                  0.944
   Free T4, pmol/L                    14.6 ± 2.8                         14.6 ± 2.7                  0.735         14.1 ± 2.7                 0.154
  **Laboratory findings**                                                                                                                     
   TC, mmol/L                         4.4 ± 1.1                          4.4 ± 1.0                   0.911         4.6 ± 1.2                  0.278
   TG, mmol/L                         1.2 (0.9, 1.8)                     1.1 (0.8, 1.8)              0.675         1.4 (1.1, 2.3)             0.018
   LDL, mmol/L                        2.6 (2.1, 3.3)                     2.8 (2.1, 3.3)              0.512         2.6 (2.1, 3.2)             0.972
   HDL, mmol/L                        1.2 ± 0.3                          1.2 ± 0.3                   0.802         1.2 ± 0.4                  0.742
   FGB, mmol/L                        6.3 ± 2.2                          6.4 ± 2.2                   0.703         6.5 ± 2.8                  0.464
   Homocysteine, umol/L               15.7 ± 9.2                         16.1 ± 7.4                  0.795         15.2 ± 8.0                 0.586
   Hs-CRP, mg/L                       5.7 (2.3, 12.3)                    8.4 (2.0, 11.6)             0.388         5.0 (2.0, 12.5)            0.343
  ----------------------------------- ---------------------------------- --------------------------- ------------- -------------------------- -------------

Abbreviations: ASPECTS: alberta stroke program early CT score; FGB: fasting blood glucose; HDL: high density lipoprotein; Hs-CRP: high-sensitivity C-reactive protein; LDL: low density lipoprotein; NIHSS: national institutes of health stroke scale; SHyper: subclinical hyperthyroidism; SHypo: subclinical hypothyroidism; sICH: symptomatic intracranial hemorrhage; TC: total cholesterol; TG: triglyceride; TSH: thyroid stimulating hormone.

\*Univariate analysis between SHyper group and euthyroidism group;

^\#^Univariate analysis between SHypo group and euthyroidism group;

^†^Data available for 525 patients.

[Table 3](#t3){ref-type="table"} demonstrated the baseline data of the study population according to clinical outcomes. Patients with END were older, had higher prevalence of endovascular therapy, vascular occlusion, sICH, large artery atherosclerosis and SHyper, and had higher baseline NIHSS score, onset to treatment time, fasting blood glucose and homocysteine levels. The ASPECTS score at 24 h was lower in patients with END than those without. Furthermore, endovascular therapy, vascular occlusion, sICH, and SHyper were more frequent in patients with 3-month poor outcome and mortality.

###### Baseline characteristics of the study population stratified by the clinical outcomes in IVT patients.

  ------------------------------- ------------------ ------------------- ------------------------------ ------------------ --------------------------- --------- ------------------- ----------------- -------
  **Variable**                    **END**            ***P***             **Poor outcome at 3 months**   ***P***            **Mortality at 3 months**   ***P***                                         
  **Yes (n = 83)**                **No (n = 480)**   **Yes (n = 286)**   **No (n = 277)**               **Yes (n = 53)**   **No (n = 510)**                                                            
  **Demographics data**                                                                                                                                                                                
   Age, year                      69.1 ± 9.6         66.2 ± 11.8         0.007                          67.5 ± 11.8        65.7 ± 11.2                 0.055     68.7 ± 12.0         66.4 ± 11.5       0.173
   Male, %                        44 (53.0)          285 (59.4)          0.277                          122 (42.7)         112 (40.4)                  0.592     27 (50.9)           302 (59.2)        0.245
  **Vascular risk factors, %**                                                                                                                                                                         
   Hypertension                   60 (72.3)          330 (68.8)          0.519                          94 (32.9)          79 (28.5)                   0.264     39 (73.6)           351 (68.8)        0.475
   Diabetes mellitus              26 (31.3)          125 (26.0)          0.316                          71 (24.8)          80 (28.9)                   0.278     13 (24.5)           138 (27.1)        0.692
   Hyperlipidemia                 10 (12.2)          62 (12.9)           0.857                          41 (14.3)          31 (11.2)                   0.271     9 (17.0)            63 (12.4)         0.340
   Coronary heart disease         18 (21.7)          81 (16.9)           0.292                          51 (17.9)          48 (17.3)                   0.860     8 (15.1)            91 (17.9)         0.613
   Atrial fibrillation            19 (22.9)          142 (29.6)          0.213                          90 (31.5)          71 (25.6)                   0.125     25 (47.2)           136 (26.7)        0.098
   Smoking                        32 (39.0)          176 (37.0)          0.723                          113 (39.5)         95 (34.9)                   0.263     17 (32.1)           191 (37.8)        0.410
  **Clinical data**                                                                                                                                                                                    
   Previous antiplatelet, %       21 (25.9)          94 (19.7)           0.197                          53 (18.5)          62 (22.8)                   0.232     11 (20.8)           104 (20.6)        0.972
   Previous statin, %             6 (7.2)            45 (9.4)            0.529                          25 (8.7)           26 (9.4)                    0.790     5 (9.4)             46 (9.0)          0.904
   SBP, mmHg                      137.7 ± 18.8       136.7 ± 17.5        0.639                          136.9 ± 18.5       136.9 ± 16.9                0.873     138.3 ± 19.4        136.8 ± 17.5      0.524
   DBP, mmHg                      87.7 ± 11.6        86.2 ± 11.9         0.215                          86.8 ± 12.9        85.7 ± 10.9                 0.284     87.8 ± 14.6         86.1 ± 11.6       0.316
   Body mass index, kg/m^2^       23.8 ± 2.8         24.2 ± 3.3          0.322                          24.2 ± 3.2         24.1 ± 3.3                  0.675     24.1 ± 4.1          24.2 ± 3.1        0.737
   Baseline NIHSS, score          14.0 (6.0, 19.0)   7.0 (4.0, 12.0)     0.001                          10.0 (5.0, 16.0)   5.0 (3.0, 10.0)             0.001     16.0 (10.0, 20.0)   7.0 (4.0, 12.0)   0.001
   OTT, minutes                   158.0 ± 63.1       142.8 ± 62.3        0.047                          164.5 ± 59         124.9 ± 60.2                0.002     158.5 ± 57.9        143.4 ± 62.8      0.095
   Endovascular therapy, %        21 (25.3)          64 (13.3)           0.005                          71 (24.8)          14 (5.1)                    0.001     17 (32.1)           68 (13.3)         0.001
  **Center, %**                                                          0.389                                                                         0.234                                           0.156
   Center 1                       42 (50.6)          197 (41.0)                                         129 (45.1)         110 (39.7)                            19 (35.8)           220 (43.1)        
   Center 2                       9 (10.8)           85 (17.7)                                          49 (17.1)          45 (16.2)                             6 (11.3)            88 (17.3)         
   Center 3                       12 (14.5)          62 (12.9)                                          41 (14.3)          33 (11.9)                             11 (20.8)           63 (12.4)         
   Center 4                       11 (13.3)          77 (16.0)                                          37 (12.9)          51 (18.4)                             7 (13.2)            81 (15.9)         
   Center 5                       9 (10.8)           59 (12.3)                                          30 (10.5)          38 (13.7)                             10 (18.9)           58 (11.4)         
  **Imaging data**                                                                                                                                                                                     
   ASPECTS at Admission           9.0 (9.0, 10.0)    9.0 (9.0, 10.0)     0.167                          9.0 (9.0, 10.0)    10.0 (9.0, 10.0)            0.205     9.0 (9.0, 10.0)     9.0 (9.0, 10.0)   0.137
   ASPECTS at 24 h                6.0 (5.0, 7.0)     8.0 (6.0, 9.0)      0.001                          6.0 (5.0, 8.0)     9.0 (7.0, 9.0)              0.001     6.0 (5.0, 7.0)      8.0 (6.0, 9.0)    0.001
   Vascular occlusion, %^†^       47 (64.4)          208 (46.2)          0.004                          150 (56.8)         105 (40.2)                  0.002     35 (66.0)           220 (46.0)        0.001
   sICH, n (%)                    22 (26.5)          8 (1.7)             0.001                          22 (7.7)           8 (2.9)                     0.012     16 (30.2)           14 (2.7)          0.001
  **Ischemic area, %**                                                   0.689                                                                         0.907                                           0.641
   Frontal lobe                   20 (24.1)          116 (24.2)                                         72 (25.2)          64 (23.1)                             14 (26.4)           122 (23.9)        
   Parietal lobe                  8 (9.6)            43 (9.0)                                           26 (9.1)           25 (9.0)                              7 (13.2)            44 (8.6)          
   Basal ganglia                  23 (27.7)          242 (29.6)                                         84 (29.4)          81 (29.2)                             14 (26.4)           151 (29.6)        
   Posterior fossa                15 (18.1)          90 (18.8)                                          49 (17.1)          56 (20.2)                             11 (20.8)           94 (18.4)         
   Other                          17 (20.5)          89 (18.5)                                          55 (19.2)          51 (18.4)                             7 (13.2)            99 (19.4)         
  **Stroke subtype, %**                                                  0.014                                                                         0.056                                           0.072
   Large artery atherosclerosis   46 (55.4)          185 (38.5)                                         122 (42.7)         109 (39.4)                            23 (43.4)           208 (40.8)        
   Cardioembolism                 21 (25.3)          120 (25.0)                                         78 (27.3)          63 (22.7)                             19 (35.8)           122 (23.9)        
   Small vessel occlusion         7 (8.4)            118 (24.6)                                         50 (17.5)          75 (27.1)                             5 (9.4)             120 (23.5)        
   Others                         9 (10.8)           57 (11.9)                                          36 (12.6)          30 (10.8)                             6 (11.3)            60 (11.8)         
  **Thyroid function status**                                            0.007                                                                         0.002                                           0.002
   Euthyroidism                   56 (67.5)          355 (74.0)                                         205 (71.7)         206 (74.4)                            33 (62.3)           378 (74.1)        
   SHyper                         19 (22.9)          37 (7.7)                                           40 (14.0)          16 (5.8)                              16 (30.2)           40 (7.8)          
   SHypo                          8 (9.6)            88 (18.3)                                          41 (14.3)          55 (19.9)                             4 (7.5)             92 (18.0)         
  **Laboratory findings**                                                                                                                                                                              
   TC, mmol/L                     4.5 ± 1.0          4.4 ± 1.1           0.636                          4.4 ± 1.1          4.5 ± 1.2                   0.261     4.2 ± 0.9           4.3 ± 1.1         0.124
   TG, mmol/L                     1.4 (0.9, 1.9)     1.4 (1.0, 2.0)      0.528                          1.3 (0.9, 2.0)     1.5 (1.0, 2.0)              0.312     1.5 (0.8, 2.2)      1.4 (1.0, 2.0)    0.942
   LDL, mmol/L                    2.7 (2.2, 3.3)     2.6 (2.1, 3.2)      0.174                          2.7 (2.1, 3.2)     2.5 (2.1, 3.1)              0.197     2.5 (2.1, 3.1)      2.6 (2.1, 3.2)    0.524
   HDL, mmol/L                    1.2 ± 0.3          1.1 ± 0.3           0.304                          1.2 ± 0.3          1.1 ± 0.3                   0.544     1.2 ± 0.2           1.2 ± 0.3         0.847
   FGB, mmol/L                    7.1 ± 2.6          6.1 ± 2.3           0.003                          6.4 ± 2.5          6.3 ± 2.3                   0.507     6.8 ± 3.1           6.2 ± 2.3         0.105
   Homocysteine, umol/L           18.1 ± 9.5         15.2 ± 8.7          0.011                          16.8 ± 8.8         15.8 ± 8.7                  0.003     16.0 ± 6.8          15.6 ± 9.1        0.695
   Hs-CRP, mg/L                   7.9 (2.4, 16.7)    5.1 (2.3, 12.2)     0.102                          5.1 (2.1, 11.4)    6.0 (2.8, 12.6)             0.384     10.0 (2.9, 17.8)    5.3 (2.2, 11.0)   0.074
  ------------------------------- ------------------ ------------------- ------------------------------ ------------------ --------------------------- --------- ------------------- ----------------- -------

Abbreviations: ASPECTS: alberta stroke program early CT score; FGB: fasting blood glucose; HDL: high density lipoprotein; Hs-CRP: high-sensitivity C-reactive protein; LDL: low density lipoprotein; NIHSS: national institutes of health stroke scale; OTT: onset to treatment time; SHyper: subclinical hyperthyroidism; SHypo: subclinical hypothyroidism; sICH: symptomatic intracranial hemorrhage; TC: total cholesterol; TG: triglyceride.

^†^Data available for 525 patients.

Center 1: Nanjing First Hospital; Center 2: Mianyang Central Hospital; Center3: The First people's Hospital of Yulin; Center 4: The Third People's Hospital of Nantong. Center 5: Jiangsu Provincial Second Chinese Medicine Hospital.

Univariate regression analysis demonstrated that SHyper was associated with increased risk of END \[odd ratio (OR), 3.26; 95% confidence interval \[CI\], 1.75--6.06, *P* = 0.001\], 3-month poor outcome (OR, 2.51; 95% CI, 1.36--4.63; *P* = 0.003) and mortality \[hazard ratio, 3.98; 95% CI, 2.24--7.43, *P* = 0.001\]. Furthermore, after adjusting for age, sex, cardiovascular risk factors, center and variables with *P* \< 0.05 in univariate analysis, this association did not significantly attenuate. However, no association was found in SHypo with clinical outcomes after IVT ([Table 4](#t4){ref-type="table"}).

###### Unadjusted and adjusted regression analysis for clinical outcomes in IVT patients.

  ------------------------- ------------------------ --------- --------------------------------------------- --------- ------------------------------------------ ---------
                            **OR (95%CI) for END**   ***P***   **OR (95%CI) for poor outcome at 3 months**   ***P***   **HR (95%CI) for mortality at 3 months**   ***P***
  Unadjusted model                                                                                                                                                
   SHyper vs Euthyroidism   3.26 (1.75--6.06)        0.001     2.51 (1.36--4.63)                             0.003     3.98 (2.24--7.43)                          0.001
   SHypo vs Euthyroidism    0.58 (0.27--1.25)        0.164     0.75 (0.48--1.17)                             0.207     0.51 (0.18--1.44)                          0.199
  Model 1                                                                                                                                                         
   SHyper vs Euthyroidism   3.96 (2.06--7.68)        0.001     3.14 (1.66--5.92)                             0.001     3.92 (2.13--7.24)                          0.001
   SHypo vs Euthyroidism    0.56 (0.25--1.23)        0.146     0.72 (0.46--1.15)                             0.167     0.48 (0.17--1.36)                          0.166
  Model 2                                                                                                                                                         
   SHyper vs Euthyroidism   4.35 (1.86--9.68)        0.003     3.24 (1.43--7.33)                             0.005     2.78 (1.55--5.36)                          0.003
   SHypo vs Euthyroidism    0.78 (0.30--2.01)        0.601     0.58 (0.30--1.12)                             0.104     0.47 (0.14--1.75)                          0.225
  ------------------------- ------------------------ --------- --------------------------------------------- --------- ------------------------------------------ ---------

Abbreviations: CI: confidence interval; END: Early neurological deterioration; HR: hazard ratio; OR: odd ratio.

Eighty-five (15.1%) patients received endovascular therapy after admission. Results of subgroup analysis according to the IVT patients with or without endovascular therapy were listed in [Table 5](#t5){ref-type="table"}. For the patients receiving IVT followed by endovascular therapy, SHypo showed a trend for predicting 3-month poor outcome (adjusted OR, 0.27; 95% CI, 0.08--1.06; *P* = 0.057), but not for END and mortality. However, no association was found in SHyper with clinical outcomes among these patients.

###### Subgroup analysis according to the IVT patients with and without endovascular therapy.

  -------------------------------------- ------------------------------------------------- -------------------- ----------------------------------------------------- --------------------- -------------------- --------------------- -------------------
  **Clinical outcomes**                  **Patients with endovascular therapy (n = 85)**                        **Patients without endovascular therapy (n = 478)**                                                                    
  **Euthyroidism (n = 60)**              **SHyper (n = 12)**                               **SHypo (n = 13)**   **Euthyroidism (n = 351)**                            **SHyper (n = 44)**   **SHypo (n = 83)**                         
  **Early neurological deterioration**                                                                                                                                                                                                 
  Unadjusted OR (95%CI)                  Reference                                         1.34 (0.36--5.20)    0.23 (0.03--1.91)                                                           Reference            4.02 (1.99--8.14)\*   0.72 (0.31--1.66)
  Adjusted OR (95%CI)                    Reference                                         1.17 (0.28--4.95)    0.22 (0.03--1.96)                                                           Reference            4.72 (2.08--9.69)\*   1.08 (0.44--2.65)
  **Poor outcome** at 3 months                                                                                                                                                                                                         
  Unadjusted OR (95%CI)                  Reference                                         1.69 (0.19--9.94)    0.25 (0.06--1.04)                                                           Reference            2.50 (1.30--4.83)\*   0.85 (0.30--4.83)
  Adjusted OR (95%CI)                    Reference                                         1.40 (0.15--9.33)    0.27 (0.08--1.06)                                                           Reference            2.54 (1.21--5.33)\*   0.84 (0.49--1.45)
  **Mortality** at 3 months                                                                                                                                                                                                            
  Unadjusted HR (95%CI)                  Reference                                         2.75 (0.85--6.54)    0.39 (0.04--2.27)                                                           Reference            4.29 (2.63--9.03)\*   0.83 (0.29--2.44)
  Adjusted HR (95%CI)                    Reference                                         1.77 (0.58--5.44)    0.37 (0.06--2.31)                                                           Reference            3.99 (1.81--9.30)\*   0.89 (0.26--3.12)
  -------------------------------------- ------------------------------------------------- -------------------- ----------------------------------------------------- --------------------- -------------------- --------------------- -------------------

Abbreviations: CI: confidence interval; OR: odd ratio; HR: hazard ratio; SHyper: subclinical hyperthyroidism; SHypo, subclinical hypothyroidism.

\**P* \< 0.05

Adjusted model was controlled for age, sICH, ASPECTS score at 24 h and vascular occlusion.

Kaplan-Meier curve revealed that mortality at 3 months was significantly higher in patients with SHyper when compared with euthyroidism. No association was detected in mortality between patients with SHypo and euthyroidism ([Figure 2](#f2){ref-type="fig"}, log-rank test, *P* = 0.001).

![**The Kaplan Meier curve for the cumulative 3-month survival rates according to the thyroid status.** Log-rank test shows significant difference between patients with SHyper and euthyroidism.](aging-11-102215-g002){#f2}

DISCUSSION
==========

In this large prospective cohort study of 563 ischemic stroke patients underwent IVT, we demonstrated that SHyper may increase the risk of END, poor outcome and mortality at 3 months in IVT patients without endovascular therapy.

The incidence of 14.7% for END in our study is similar to two recently published series of IVT-treated patients sharing the same END definition \[[@r25], [@r26]\]. Several risk factors have been postulated to lead to thrombolysis END, such as high blood glucose, hemorrhagic transformation, thrombus extension, and persistent arterial occlusion \[[@r25]--[@r27]\]. Data is scarce regarding the effect of neuroendocrine factors on mediating clinical outcomes after IVT. It is now believed that thyroid dysfunction is a potential mediator of the presence and outcome of cerebrovascular diseases. SHypo has been reported to be associated with favorable prognosis, while SHyper related to poor outcomes \[[@r17], [@r18]\]. Several other studies demonstrate that SHypo and elevated serum TSH level were correlated to increased risk of atherosclerosis \[[@r28], [@r29]\]. Cases of severe SHypo showed obvious exacerbation of carotid atherosclerosis \[[@r28]\]. In contrast, Cikim et al. found that SHypo was not associated with carotid atherosclerosis, but rather with decreased carotid artery intima-media thickness \[[@r30]\]. Interestingly, our present data did not show a remarkable association of SHypo with large artery atherosclerotic ischemic stroke and vascular occlusion. Some of these discrepancies might be explained at least in part by differences concerning the study population and methodology, especially the assessment of subclinical thyroid dysfunction.

More recently, high TSH levels were demonstrated to be independently correlated with a decreased risk of NIHSS score ≥ 5 at admission (prevalence proportion ratios, 0.62; 95% CI, 0.41--0.94, *P* = 0.024 for 3^rd^tertile vs. 1^st^ tertile) \[[@r31]\]. In addition, patients with high TSH levels may have a better functional outcome at discharge \[[@r31]\]. To our best knowledge, this is the first prospective study that assessed subclinical thyroid dysfunction pattern specifically in relation to clinical outcomes in IVT patients and found that SHyper may increase the risk of END and worse outcome at 3 months. Consistent with our hypothesis, the multivariable logistic regression analysis revealed an independent association between SHyper and END even after adjusting for age, NIHSS score, stroke subtypes, onset to treatment time, sICH, fasting blood glucose levels, homocysteine levels, ASPECTS score at 24 h after thrombolysis and vascular occlusion. There are several mechanisms that might explain for the negative effects of SHyper on worse outcome in patients receiving IVT. Firstly, elevated concentrations of thyroid hormones are associated with an increase in metabolic rate and hyperactive condition in neural tissues, which would be susceptible to the amplitude of neurological damage after ischemia-reperfusion \[[@r32]\]. Secondly, SHyper can cause hypercoagulable state \[[@r16], [@r33]\], negatively affecting the utility of IVT. Also, pro-inflammatory in SHyper is prone to result in endothelial dysfunction \[[@r16]\], an important pathogenetic role in the progression of stroke and unfavorable outcomes.

In the subgroup analysis of patients treated with IVT followed by endovascular therapy, SHypo showed a protective effect on functional outcome at 3 months. A reduced response under condition of SHypo has been viewed as a protective preconditioning before stroke \[[@r7], [@r17], [@r24]\]. Additionally, long-lasting SHypo inducing atherosclerosis in cerebral vessels may also contribute to the development of collateral vessels, which has been widely accepted to be associated with better clinical outcome after endovascular therapy \[[@r34]\]. However, we could not establish an association of SHyper with worse outcome in these patients. These results should be extended and confirmed in future studies.

The strengths of our study include its prospective design and multiple-centers with large sample size. Also, there are limitations to this study that should be considered when interpreting the results. Firstly, some studies have shown the association of neuro-imaging markers such as thrombus extension, persistent arterial occlusion and vascular recanalization with END. However, these markers were not measured in this study, and we did not exclude effects of these markers on END. Also, we cannot totally exclude the potential effect of other undetected factors such as drug, stress induced by stroke, disease status and genetic predisposition on the level of thyroid function. Secondly, FT3, FT4, and TSH concentrations were measured only once at admission. A serial test would also be useful in verifying the role of thyroid function as a predisposing factor on acute stroke outcomes. Finally, several patients transfer to other hospitals or discharge early, presumably because of severe neurological deficit. Exclusion of such patients might have underestimated the prevalence of END and poor outcome.

In conclusion, this study illustrates that SHyper might be associated with increased risk of END, 3-month poor outcome and mortality in IVT patients without endovascular therapy. The potential benefits of screening and intervention of thyroid function on early clinical recovery require further exploration in ischemic patients underwent IVT.

MATERIALS AND METHODS
=====================

Study population
----------------

From January 2017 to March 2018, we consecutively recruited acute ischemic stroke patients underwent IVT within 4.5 h of symptom onset at 5 stroke centers in China (Nanjing First Hospital, Mianyang Central Hospital, The First people's Hospital of Yulin, The Third People's Hospital of Nantong, and Jiangsu Provincial Second Chinese Medicine Hospital). Patients treated with a bridging therapy consisting of IVT followed by endovascular therapy were also included. Exclusion criteria were as follows: (1) hospital transfer or discharged within 24 h; (2) pre-stroke modified Rankin Scale (mRS) score \> 2; (3) pre-existing thyroid glands diseases, anti-thyroid medications, or diseases that might affect thyroid function \[[@r35], [@r36]\]; (3) defined as any of the following thyroid function alterations after admission: implausible thyroid function, biochemically defined overt thyroid disease, and non-thyroidal illness syndrome \[[@r37]\]. All participants signed a written consent form, and the study protocol was approved by the Institutional Review Board at each hospital.

Clinical data collection and assessment criteria
------------------------------------------------

Data collection was performed by neurologists with experience in stroke care using a standardized case report form. We recorded baseline characteristics, including demographics, cardiovascular risk factors (including hypertension, diabetes, hyperlipidemia, smoking, drinking, and atrial fibrillation) and previous medication. Moreover, body mass index, blood pressure, onset to-treatment time, imaging data, and stroke subtype were also recorded. In this study, symptomatic intracerebral hemorrhage (sICH) was defined according to the European Cooperative Acute Stroke Study II (ECASS-II) trial \[[@r38]\]. All computed tomography images at admission and 24 h after IVT were calculated for the Alberta Stroke Program Early CT Scores (ASPECTS) \[[@r39]\]. Computed tomography angiography, magnetic resonance angiography or digital subtraction angiography was performed to identify the affected vessel. Stroke subtype was classified according to TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria \[[@r40]\].

Thyroid function tests
----------------------

Blood samples were obtained from all patients within 24h after onset, and collected in chemistry test tubes. After centrifugation, serum samples were separated, and kept frozen at −80 °C for later analysis. Free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH) levels were determined for each patient by electrochemiluminescence immunoassay (Abbott Architect i2000, Abbott Diagnostics, Abbott Park, IL, USA). In accordance with previous studies \[[@r9], [@r18]\], levels of thyroid function were defined as SHyper \[0.1 \< TSH \< 0.45 mIU/L\], and SHypo (TSH: 2.50--19.99 mIU/L) with thyroid function test results. Patients with serum TSH levels between 0.45--2.49 mIU/L were considered as control group. Reference ranges for FT4 were 11.58--23.16pmol/L and for FT3 were 3.54--6.46pmol/L.

Clinical outcomes measurement
-----------------------------

The primary outcome was END, which was defined as an increment of at least 4 point in total NIHSS score between admission and within 24 h after IVT (2). During a follow-up at 3 months after the index stroke, all patients were assessed for clinical outcome using the modified Rankin Scale (mRS) by neurologists who were blinded to clinical data. The following secondary outcomes were recorded: (1) functional outcome: categorized as good (mRS score of 0--2) and poor (mRS score of 3--6); (2) mortality.

Statistical analysis
--------------------

All statistical analysis was done with SPSS software, version 23.0 (SPSS Inc., Chicago, IL). Continuous variables were summarized as mean ± standard deviations (SD) or medians with interquartile ranges (IQR) and compared by Student\'s t test or Mann-Whitney U test as appropriate. Categorical variables were expressed as percentages and analyzed with the chi-square test or Fisher's exact test, as appropriate. Binary logistic regression analysis was designed to describe adjusted estimates of the association of subclinical thyroid dysfunction with END and poor outcome at 3 months. Cox's proportional hazard regression analysis was performed to estimate the hazard ratio for mortality. All regression analyses were first adjusted for age, sex, cardiovascular risk factors and center (Model 1), and additionally adjusted for variables with *P* \< 0.05 in univariate analysis (Model 2). We also used Kaplan-Meier curve to calculate 3-month survival probabilities. In all analyses, *P* \< 0.05 was considered as statistically significant.
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